Silo Pharma (NASDAQ: SILO) has announced a partnership with Veloxity Labs to conduct GLP-compliant bioanalysis for its SPC-15 intranasal treatment study, aimed at preventing PTSD. This collaboration marks a significant step towards submitting an investigational new drug application to the FDA by 2025. The success of this study could lead to a Phase 1 human clinical trial, offering new hope for individuals suffering from PTSD and stress-induced anxiety disorders.
The partnership underscores Silo Pharma's commitment to addressing underserved conditions through innovative therapeutics. SPC-15 represents a novel approach to treating PTSD, a condition that affects millions worldwide. The company's focus on psychedelic treatments and traditional therapies in new formulations highlights the growing interest in alternative mental health treatments.
For more details on Silo Pharma's initiatives, visit https://www.SiloPharma.com. Updates on SILO can be found at https://ibn.fm/SILO.
